Skip to main content

Table 2 Demographics, baseline clinical data, and CT scores at baseline and last CT grouped by osteitis severity at last CT

From: Impact of baseline clinical and radiological features on outcome of chronic rhinosinusitis in granulomatosis with polyangiitis

  No osteitis, Moderate osteitis, Severe osteitis,
  n = 45 n = 34 n = 37
Demographic data
Women; n (%) 23 (51) 15 (44) 15 (41)
Limited GPA, as defined in WGET research group; n (%) 18 (40) 15 (44) 19 (51)
Mean age at diagnosis in years (SD) 44 (20) 54 (18) 39 (18)
Median time in years between symptom onset and diagnosis (range) 44; 0.4 (0.0–9.3) 0.7 (0.0–6.0) 0.4 (0.1–10.0)
  Missing = 1   
Median time in years from diagnosis to first CT (range) 0.1 (−3.9–18.5) 0.3 (−2.3–16.1) 0.5 (−1.3–24.6)
Median time in years between first and last CT (range) 4.5 (1.3–12.9) 4.8 (1.1–13.5) 7.3 (2.1–14.7)
Ever smokers; fraction (%) 17/36 (47) 14/30 (47) 17/28 (61)
Mortality; n (%) 3 (7) 3 (9) 4 (11)
Laboratory data
ANCA positive; fraction (%) 44/45 (98) 33/33 (100) 32/32 (100)
ANCA negative; fraction (%) 1/45 (2.2) 0/33 (0) 0/32 (0)
Baseline clinical data, BVAS
General; n (%) 42 (93) 32 (94) 33 (89)
Cutaneous; n (%) 11 (24) 7 (21) 8 (22)
Mucosal membranes/eyes; n (%) 14 (31) 10 (29) 9 (24)
Ear, nose, and throat; n (%) 42 (93) 29 (85) 36 (97)
Bloody nasal discharge/crusts/ulcers/granulomata; n (%) 35 (78) 25 (74) 33 (89)
Paranasal sinus involvement; n (%) 23 (51) 23 (68) 33 (89)
Subglottic stenosis; n (%) 0 (0) 0 (0) 0 (0)
Conductive hearing loss; n (%) 15 (33) 6 (18) 12 (32)
Sensorineural hearing loss; n (%) 5 (11) 1 (3) 1 (3)
Chest; n (%) 26 (58) 21 (62) 22 (59)
Cardiovascular; n (%) 1 (2) 0 (0) 0 (0)
Abdominal; n (%) 3 (7) 1 (3) 2 (5)
Renal; n (%) 27 (60) 20 (59) 15 (41)
Nervous system; n (%) 7 (16) 4 (12) 10 (27)
Surgery at end of follow-up
Sinus surgery; n (%) 1 (2) 4 (12) 17 (46)
CT scores at baseline
Median GOSS (range) 0 (0–0) 2 (0–18) 6 (0–38)
Sinonasal destructions; n (%) 3 (7) 6 (18) 20 (54)
Nasal septum perforation; n (%) 3 (7) 4 (12) 5 (14)
Saddle nose deformity; n (%) 2 (4) 1 (3) 5 (14)
Median LM-score (range) 1 (0–12) 4 (0–22) 9 (0–22)
LM-score >0; n (%) 29 (64) 30 (88) 36 (97)
CT scores at last CT
Median GOSS (range) 0 (0–0) 4 (1–28) 16 (5–49)
Sinonasal destructions; n (%) 6 (13) 11 (32) 33 (89)
Nasal septum perforation; n (%) 6 (13) 7 (21) 13 (35)
Saddle nose deformity; n (%) 2 (4) 4 (12) 10 (27)
Median LM-score (range) 1 (0–7) 4 (0–20) 7 (0–22)
  1. Missing data on ANCA and smoking
  2. Abbreviations:GPA granulomatosis with polyangiitis, WGET Wegener’s Granulomatosis Etanercept Trial, ANCA anti-neutrophil cytoplasmic antibodies, BVAS Birmingham Vasculitis Activity Score, version 3, GOSS Global Osteitis Scoring Scale, LM-score Lund-Mackay score